Teva to pay $4.25bn over 13 years under agreement in principle with 12 state attorneys general, Native American tribes and plaintiffs’ lawyers. Previous settlement offer provided mostly medication. Deal is contingent on governments signing on and Allergan inking settlement.

Tufts study evaluates the extent and impact of manufacturer engagement with the Institute for Clinical and Economic Review while recent survey by Xcenda finds payer reliance on ICER reports is growing.

According to a report commissioned by PhRMA, the three largest pharmacy benefit managers continue to exclude more drugs from standard formularies, including those with expedited FDA approval. 

Private Company Edition: 5AM revealed two funds totaling $450m and $300m, V-Bio raised a €110m venture capital fund and AXA IM Alts committed $500m for health care private equity deals. Also, TRIANA launched with $110m and the AMR Action Fund backs Adaptive Phage Therapeutics.